ライフサイエンスコーパス: docetaxel

1 umetinib + docetaxel; 254 received placebo + docetaxel).

2 3 given 10 mg/kg, and 109 [35%] of 309 given docetaxel).

3 29 to doxorubicin and 128 to gemcitabine and docetaxel).

4 ted agents (imatinib), and cytotoxic agents (docetaxel).

5 irradiation or chemotherapy (gemcitabine or docetaxel).

6 atients received second-line nintedanib plus docetaxel.

7 xicity compared with equimolar doses of free docetaxel.

8 ab or placebo in addition to trastuzumab and docetaxel.

9 QR, 2.3-7.3; 95% CI, 2.8-5.6) with placebo + docetaxel.

10 line plus paclitaxel, and anthracycline plus docetaxel.

11 pembrolizumab 10 mg/kg, and 343 allocated to docetaxel.

12 iation exposure but increased sensitivity to Docetaxel.

13 atients treated with nivolumab compared with docetaxel.

14 st one dose of atezolizumab and 135 received docetaxel.

15 pembrolizumab 10 mg/kg, and 8.5 months with docetaxel.

16 eneficial when combined with trastuzumab and docetaxel.

17 s cyclophosphamide, followed by 4 courses of docetaxel.

18 survival was longer with nivolumab than with docetaxel.

19 tumor cell proliferation compared with free docetaxel.

20 tant prostate cancer previously treated with docetaxel.

21 nib + docetaxel and 256 to receive placebo + docetaxel.

22 ab and 425 patients were assigned to receive docetaxel.

23 .0008) and for pembrolizumab 10 mg/kg versus docetaxel (0.61, 0.49-0.75; p<0.0001).

24 difference for pembrolizumab 2 mg/kg versus docetaxel (0.88, 0.74-1.05; p=0.07) or for pembrolizumab

25 ), respectively, x four cycles), followed by docetaxel (100 mg/m(2) x four cycles; EC-T) or epirubici

26 de (600 mg/m(2)) followed by three cycles of docetaxel (100 mg/m(2); EC-D).

27 higher were more frequent with selumetinib + docetaxel (169 adverse events [67%] for selumetinib + do

28 2) and with pembrolizumab 10 mg/kg than with docetaxel (17.3 months vs 8.2 months; 0.50, 0.36-0.70; p

29 t 1 year was higher with nivolumab than with docetaxel (19% and 8%, respectively).

30 ezolizumab (90 [15%] of 609 patients) versus docetaxel (247 [43%] of 578 patients).

31 rience grade 2 to 4 neuropathy compared with docetaxel (25% v 12%, respectively; OR, 2.20; 95% CI, 1.

32 pleted the study (251 received selumetinib + docetaxel; 254 received placebo + docetaxel).

33 nts received vinorelbine, 343 (23%) received docetaxel, 283 (19%) received gemcitabine, and 497 (33%)

34 rexate (40-60 mg/m(2) of body surface area), docetaxel (30-40 mg/m(2)), or cetuximab (250 mg/m(2) aft

35 ere less common with pembrolizumab than with docetaxel (43 [13%] of 339 patients given 2 mg/kg, 55 [1

36 in versus those who received gemcitabine and docetaxel (46.3% [95% CI 37.5-54.6] vs 46.4% [37.5-54.8]

37 1) and with pembrolizumab 10 mg/kg than with docetaxel (5.2 months vs 4.1 months; 0.59, 0.45-0.78; p<

38 (2) (C20) or 25 mg/m(2) (C25) is superior to docetaxel 75 mg/m(2) (D75) in terms of OS in patients wi

39 erapy (intravenous pemetrexed 500 mg/m(2) or docetaxel 75 mg/m(2) [investigator choice], every 21 day

40 ously receive either atezolizumab 1200 mg or docetaxel 75 mg/m(2) every 3 weeks by permuted block ran

41 physician's choice of a taxane (intravenous docetaxel 75 mg/m(2) every 3 weeks or intravenous paclit

42 olizumab 2 mg/kg, pembrolizumab 10 mg/kg, or docetaxel 75 mg/m(2) every 3 weeks.

43 ts were randomly assigned (1:1:1) to receive docetaxel 75 mg/m(2) intravenously (IV) on day 1 of a 3-

44 All patients received docetaxel 75 mg/m(2) intravenously with 5 mg of predniso

45 kg IV on day 1 of a 3-week cycle (arm B), or docetaxel 75 mg/m(2) IV on day 1 plus icrucumab 12 mg/kg

46 sly (IV) on day 1 of a 3-week cycle (arm A), docetaxel 75 mg/m(2) IV plus ramucirumab 10 mg/kg IV on

47 675 mg/m(2) on days 1 and 8 and intravenous docetaxel 75 mg/m(2) on day 8 every 3 weeks.

48 receive intravenous atezolizumab 1200 mg or docetaxel 75 mg/m(2) once every 3 weeks.

49 Docetaxel 75 mg/m(2) or pemetrexed 500 mg/m(2) once ever

50 e web response system to receive intravenous docetaxel 75 mg/m(2) plus either intravenous ramucirumab

51 arboplatin, and trastuzumab plus pertuzumab (docetaxel 75 mg/m(2); carboplatin area under the concent

52 1:1 to nivolumab (3 mg/kg every 2 weeks) or docetaxel (75 mg/m(2) every 3 weeks).

53 ose, followed by 6 mg/kg every 3 weeks) plus docetaxel (75 mg/m(2) every 3 weeks, increasing to 100 m

54 cycles 2-8) in conjunction with neoadjuvant docetaxel (75 mg/m(2) on day 1 of cycles 1-4) and FEC (f

55 of vinorelbine (30 mg/m(2) on days 1 and 8), docetaxel (75 mg/m(2) on day 1), gemcitabine (1200 mg/m(

56 e randomly assigned to receive six cycles of docetaxel (75 mg/m(2)) and cyclophosphamide (600 mg/m(2)

57 kly cycles, then 4-weekly until 2 years, and docetaxel (75 mg/m(2)) for six 3-weekly cycles with pred

58 nt prostate cancer in a 1:1 ratio to receive docetaxel (75 mg/m(2)) on day 1 and prednisone (5 mg twi

59 ata available for analysis; g differentiated docetaxel (a US Food and Drug Administration-approved th

60 ave a predictive impact on chemotherapy with docetaxel, a widely used drug in patients with metastati

61 Fixed-dose rate gemcitabine plus docetaxel achieves objective response in 35% of patients

62 s associated with even greater efficacy than docetaxel across all end points in subgroups defined acc

63 uld be 33.3% longer among patients receiving docetaxel added to ADT early during therapy than among p

64 ne-sensitive prostate cancer irrespective of docetaxel administration.

65 se compared with those given trastuzumab and docetaxel after surgery.

66 /m(2) days 1 and 8 intravenously, 75 mg/m(2) docetaxel), all followed by neoadjuvant doxorubicin and

67 esistant prostate cancer cells and tumors to docetaxel, allowing a four-fold reduction in effective d

68 -based neoadjuvant regimens for four cycles: docetaxel alone (100 mg/m(2)) with addition of capecitab

69 with either docetaxel with PANVAC (arm A) or docetaxel alone (arm B).

70 (MEK) inhibitor selumetinib + docetaxel with docetaxel alone as a second-line therapy for advanced KR

71 E trial is a 2 x 2 factorial trial comparing docetaxel alone or with ZA, Sr89, or both.

72 rove progression-free survival compared with docetaxel alone.

73 Up to 10 cycles of docetaxel alone; docetaxel with ZA; docetaxel with a sin

74 associated with longer overall survival than docetaxel among patients with previously treated non-sma

75 e response rate was 20.1% with selumetinib + docetaxel and 13.7% with placebo + docetaxel (difference

76 ile range [IQR], 1.5-5.9) with selumetinib + docetaxel and 2.8 months (IQR, 1.4-5.5) with placebo + d

77 randomized 1:1; 254 to receive selumetinib + docetaxel and 256 to receive placebo + docetaxel.

78 1.7-4.8; 95% CI, 2.7-4.1) with selumetinib + docetaxel and 4.5 months (IQR, 2.3-7.3; 95% CI, 2.8-5.6)

79 .7 months (IQR, 3.6-16.8) with selumetinib + docetaxel and 7.9 months (IQR, 3.8-20.1) with placebo +

80 Men with progressive mCRPC after docetaxel and abiraterone and/or enzalutamide were rando

81 nts with mCRPC and progressive disease after docetaxel and abiraterone and/or enzalutamide.

82 Docetaxel and cabazitaxel improve overall survival compa

83 acid) (PLGA) core and lipid layer containing docetaxel and clinically used inhibitor of sphingosine k

84 Purpose Docetaxel and cyclophosphamide (TC) was superior to doxo

85 t-cycle chemotherapy from 2008 to 2013 using docetaxel and cyclophosphamide (TC); docetaxel, carbopla

86 Docetaxel and cyclophosphamide for four cycles is an acc

87 We loaded these LPS-Lips with docetaxel and evaluated the potential of ATB(0,+)-mediat

88 Two breast cancer drugs, docetaxel and HER2-targeted lapatinib, were delivered to

89 VENICE trial, and 470 patients treated with docetaxel and placebo in the ENTHUSE 33 trial.

90 nd custirsen group (n=501) compared with the docetaxel and prednisone alone group (n=499) were neutro

91 nd custirsen group and 24 (5%) deaths in the docetaxel and prednisone alone group.

92 el, prednisone, and custirsen combination or docetaxel and prednisone alone.

93 and custirsen and 181 (36%) of 499 receiving docetaxel and prednisone alone.

94 ination, compared with patients treated with docetaxel and prednisone alone.

95 Sphere, comprising 476 patients treated with docetaxel and prednisone from the ASCENT2 trial, 526 pat

96 i-angiogenic properties, in combination with docetaxel and prednisone in chemotherapy-naive patients

97 the effect of custirsen in combination with docetaxel and prednisone on overall survival in patients

98 ETATION: Addition of custirsen to first-line docetaxel and prednisone was reasonably well tolerated,

99 nisone, and custirsen and 512 were allocated docetaxel and prednisone.

100 nd custirsen vs 22.0 months [19.5-24.0] with docetaxel and prednisone; hazard ratio [HR] 0.93, 95% CI

101 l benefit with the addition of pertuzumab to docetaxel and trastuzumab (THP) as first-line treatment

102 phamide), followed by 3 cycles of concurrent docetaxel and trastuzumab, followed by maintenance trast

103 interventions (prednisone, mitoxantrone, and docetaxel) and off-treatment data when on-study treatmen

104 o microtubule stabilizing drugs (paclitaxel, docetaxel) and Plk1 inhibitor (BI2536).

105 rophobic drug loading capacity (up to 25 wt% docetaxel) and tunable properties.

106 atin-based doublet, 64.9% and 31.3% received docetaxel, and 0% and 23.0% received best supportive car

107 subanalysis; 358 were treated with ADT plus docetaxel, and 361 were treated with ADT alone.

108 chemotherapeutic agents, namely, cisplatin, docetaxel, and 5-fluorouracil.

109 atoid tumors to the PARP inhibitor olaparib, docetaxel, and doxorubicin.

110 vity to three chemotherapy drugs: cisplatin, docetaxel, and doxorubicin.

111 s that can limit the efficacy of paclitaxel, docetaxel, and the vinca alkaloids.

112 therapy (40 [34%] to pemetrexed, 73 [63%] to docetaxel, and three [3%] discontinued before receiving

113 e events were lower with nivolumab than with docetaxel (any grade, 68% v 88%; grade 3 to 4, 10% v 55%

114 per kilogram of body weight every 2 weeks or docetaxel at a dose of 75 mg per square meter of body-su

115 n + cyclophosphamide followed by 4 cycles of docetaxel at conventional doses) and 55 received a dose-

116 e prostate cancer to receive either ADT plus docetaxel (at a dose of 75 mg per square meter of body-s

117 er kilogram of body weight every 2 weeks, or docetaxel, at a dose of 75 mg per square meter of body-s

118 Patients received one of three docetaxel-based neoadjuvant regimens for four cycles: do

119 Preclinical data have shown that docetaxel can modify tumor phenotype, making tumor cells

120 mide, paclitaxel, and trastuzumab (ACTH) and docetaxel, carboplatin, and trastuzumab (TCH).

121 3 using docetaxel and cyclophosphamide (TC); docetaxel, carboplatin, and trastuzumab (TCH); or doxoru

122 dministered concurrently with trastuzumab or docetaxel, carboplatin, and trastuzumab for six cycles a

123 most common grade 3-4 adverse events in the docetaxel, carboplatin, and trastuzumab plus pertuzumab

124 g loading dose, 420 mg maintenance doses) or docetaxel, carboplatin, and trastuzumab plus pertuzumab

125 group and 123 (55.7%) of 221 patients in the docetaxel, carboplatin, and trastuzumab plus pertuzumab

126 tuzumab emtansine plus pertuzumab (n=223) or docetaxel, carboplatin, and trastuzumab plus pertuzumab

127 emotherapy plus dual HER2-targeted blockade (docetaxel, carboplatin, and trastuzumab plus pertuzumab)

128 [1%] of 223 patients vs 11 [5%] of 219 with docetaxel, carboplatin, and trastuzumab plus pertuzumab)

129 treatment, compared with patients receiving docetaxel, carboplatin, and trastuzumab plus pertuzumab,

130 her trastuzumab emtansine plus pertuzumab or docetaxel, carboplatin, and trastuzumab plus pertuzumab.

131 se who had received previous treatments with docetaxel, CD137 agonists, anti-CTLA4, or therapies targ

132 a new molecular mechanism of prostate cancer docetaxel chemoresistance mediated by the mammalian targ

133 These findings suggest that continuation of docetaxel chemotherapy contributes to the survival benef

134 Docetaxel chemotherapy, given at the time of long-term h

135 -resistant prostate cancer progressing after docetaxel chemotherapy.

136 urvival was 13.6 months longer with ADT plus docetaxel (combination therapy) than with ADT alone (57.

137 and 25 patients, respectively, in the three docetaxel comparator groups).

138 combination, patients on DPL received fewer docetaxel cycles (median, 6) vs 8 cycles in the control

139 arms, we investigated whether the number of docetaxel cycles administered to patients deriving clini

140 To investigate whether the number of docetaxel cycles administered to patients deriving clini

141 Total number of docetaxel cycles delivered as an independent factor for

142 s, patients who received a greater number of docetaxel cycles had superior OS; patients who received

143 The optimal total number of docetaxel cycles in patients with metastatic castration

144 n which g was used as the endpoint, compared docetaxel data with mitoxantrone data and showed that sm

145 Cabazitaxel and docetaxel demonstrated different toxicity profiles, with

146 omparing the PD-L1 inhibitor atezolizumab to docetaxel did not demonstrate improved survival for atez

147 cell lung cancer, addition of selumetinib to docetaxel did not improve progression-free survival comp

148 nd 7.9 months (IQR, 3.8-20.1) with placebo + docetaxel (difference, 0.9 months; HR, 1.05 [95% CI, 0.8

149 and 2.8 months (IQR, 1.4-5.5) with placebo + docetaxel (difference, 1.1 months; hazard ratio [HR], 0.

150 metinib + docetaxel and 13.7% with placebo + docetaxel (difference, 6.4%; odds ratio, 1.61 [95% CI, 1

151 el vs 115 adverse events [45%] for placebo + docetaxel; difference, 22%).

152 ogy Research (USOR) 06-090 compared TC6 with docetaxel, doxorubicin, and cyclophosphamide (TAC6).

153 s) at low concentrations in conjunction with docetaxel (DTX) to overcome drug resistance of triple ne

154 We first demonstrated that curcumin, like docetaxel (DTX), can selectively target CD11b(+)Ly6G(+)L

155 Capecitabine administration with docetaxel, epirubicin, and cyclophosphamide did not prol

156 vant capecitabine to a regimen that contains docetaxel, epirubicin, and cyclophosphamide improves sur

157 m(2) x four cycles; EC-T) or epirubicin plus docetaxel (ET; 90 and 75 mg/m(2), respectively, x four c

158 followed by 4 cycles of tailored dose-dense docetaxel every 2 weeks, or to standard-interval chemoth

159 e randomly assigned to receive paclitaxel or docetaxel every 3 weeks for four doses or weekly for 12

160 hamide every 3 weeks followed by 3 cycles of docetaxel every 3 weeks.

161 urthermore, mice treated with alphavbeta3-MP-docetaxel exhibited a significant decrease in bone-resid

162 of 126 patients who received gemcitabine and docetaxel), febrile neutropenia (26 [20%] and 15 [12%]),

163 nts in patients who received gemcitabine and docetaxel, fever (18 [12%] and 19 [15%]), and neutropeni

164 f fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) followed by surgery and 4 postoperative

165 About half received 3 cycles of docetaxel followed by 3 cycles of cyclophosphamide, epir

166 hether adding capecitabine or gemcitabine to docetaxel followed by doxorubicin plus cyclophosphamide

167 The addition of bevacizumab to gemcitabine-docetaxel for first-line treatment of metastatic uLMS fa

168 Fifty-three men treated with docetaxel for mCRPC were tested for somatic BRCA1/2 muta

169 We identified 11 trials of docetaxel for men with locally advanced disease (M0).

170 apecitabine into a regimen of epirubicin and docetaxel for node-positive early BC.

171 and those who received 4 or fewer cycles of docetaxel for other reasons, minimizing the effect of co

172 o to first-line therapy with trastuzumab and docetaxel for patients with locally recurrent, unresecta

173 carboplatin-based doublet for fit patients, docetaxel for vulnerable patients, and best supportive c

174 tion with taxane chemotherapy (paclitaxel or docetaxel) for 24 weeks.

175 Continuous wave laser-induced release of docetaxel from a nanoshell-based DNA host complex showed

176 % CI, 8.1 to 10.7) among 290 patients in the docetaxel group (hazard ratio for death, 0.73; 96% CI, 0

177 umab group versus three (2%) patients in the docetaxel group died from a treatment-related adverse ev

178 No patient in either docetaxel group had an ongoing response.

179 izumab group versus 52 (39%) patients in the docetaxel group had treatment-related grade 3-4 adverse

180 2 in the atezolizumab group and n=110 in the docetaxel group) or non-squamous (0.73 [0.60-0.89]; n=31

181 piratory tract infection was reported in the docetaxel group.

182 ed to the atezolizumab group, and 143 to the docetaxel group.

183 verse events versus 30 (22%) patients in the docetaxel group.

184 p and 80 (63%) of 128 in the gemcitabine and docetaxel group.

185 y 420 mg every 3 weeks) and trastuzumab plus docetaxel (group B), pertuzumab and trastuzumab (group C

186 and trastuzumab (group C), or pertuzumab and docetaxel (group D).

187 1 and VEGF expression, while low dose (5 nM) docetaxel had no significant effect.

188 de mice, RAD001 alone or in combination with docetaxel has suppressed tumour growth, VEGF expression

189 ntly longer for pembrolizumab 2 mg/kg versus docetaxel (hazard ratio [HR] 0.71, 95% CI 0.58-0.88; p=0

190 tezolizumab versus 9.7 months (8.6-12.0) for docetaxel (hazard ratio [HR] 0.73 [95% CI 0.53-0.99]; p=

191 death was 41% lower with nivolumab than with docetaxel (hazard ratio, 0.59; 95% CI, 0.44 to 0.79; P<0

192 lumab and 6.0 months for those randomized to docetaxel (hazard ratio, 0.59; 95% CI, 0.44-0.79; P < .0

193 p=0.07) or for pembrolizumab 10 mg/kg versus docetaxel (HR 0.79, 95% CI 0.66-0.94; p=0.004).

194 o evidence of a benefit from the addition of docetaxel (HR 0.87 [95% CI 0.69-1.09]; p=0.218), whereas

195 atezolizumab vs 10.3 months [8.8-12.0] with docetaxel; HR 0.74 [95% CI 0.58-0.93]; p=0.0102).

196 ed doublet if PS </= 1 and age </= 75 years; docetaxel if PS = 2 or age > 75 years) and treatment all

197 Strontium-89 combined with docetaxel improved CPFS but did not improve OS, SRE-free

198 trials (2348 [59%] of 3978 men) showed that docetaxel improved failure-free survival (0.70 [0.61-0.8

199 Docetaxel in addition to standard of care also improved

200 icacy and safety of docetaxel monotherapy or docetaxel in combination with ramucirumab (vascular endo

201 A2 mutation showed a response rate of 25% to docetaxel in comparison to 71.1% in men with wildtype BR

202 ive eligible randomised controlled trials of docetaxel in men with metastatic (M1) disease.

203 protein 1 inhibitor nivolumab compared with docetaxel in patients with both squamous and nonsquamous

204 ignificantly improved survival compared with docetaxel in patients with previously treated NSCLC.

205 ledronic acid (ZA) is commonly combined with docetaxel in practice but lacks evidence that combining

206 ody, has demonstrated improved survival over docetaxel in previously treated advanced non-small-cell

207 evant improvement of overall survival versus docetaxel in previously treated non-small-cell lung canc

208 evant improvement of overall survival versus docetaxel in previously treated non-small-cell lung canc

209 d efficacy and safety of atezolizumab versus docetaxel in previously treated NSCLC, analysed by PD-L1

210 favorable tolerability profile compared with docetaxel in previously treated patients with advanced N

211 We assessed its efficacy and safety versus docetaxel in previously treated patients with non-small-

212 events occurred during the administration of docetaxel in the two groups, with long-term cardiac safe

213 or, prolonged overall survival compared with docetaxel in two independent phase III studies in previo

214 lamide) or antimitotic drugs (paclitaxel and docetaxel) in a variety of cancer cells expressing wild-

215 Adding docetaxel increased the likelihood of a lower PSA and im

216 The addition of docetaxel increased the likelihood of achieving a PSA </

217 s including simvastatin-induced myopathy and docetaxel-induced neutropenia.

218 /m(2), paclitaxel 175 mg/m(2), or 75 mg/m(2) docetaxel) intravenously every 3 weeks.

219 Resistance to docetaxel is a key problem in current prostate and breas

220 une checkpoint inhibitor after chemotherapy, docetaxel is recommended; in patients with nonsquamous N

221 the best of our knowledge, ramucirumab plus docetaxel is the first regimen in a phase 3 study to sho

222 month PSA </= 0.2 ng/mL was more likely with docetaxel, low-volume disease, prior local therapy, and

223 longer with pembrolizumab 2 mg/kg than with docetaxel (median 14.9 months vs 8.2 months; HR 0.54, 95

224 mucirumab plus docetaxel versus placebo plus docetaxel (median 4.07 months [95% CI 2.96-4.47] vs 2.76

225 longer with pembrolizumab 2 mg/kg than with docetaxel (median 5.0 months vs 4.1 months; HR 0.59, 95%

226 was improved with atezolizumab compared with docetaxel (median overall survival was 13.8 months [95%

227 n-free survival did not favor nivolumab over docetaxel (median, 2.3 months and 4.2 months, respective

228 The addition of ramucirumab to docetaxel met the prespecified efficacy end point for pr

229 is trial assessed the efficacy and safety of docetaxel monotherapy or docetaxel in combination with r

230 ), LPS-Lips exhibited the ability to deliver docetaxel more efficiently into tumor cells with consequ

231 randomized to receive nivolumab (n = 135) or docetaxel (n = 137).

232 xty-three patients were randomly assigned to docetaxel (n = 41) or cabazitaxel (n = 22); 44.4% receiv

233 oved with atezolizumab (n=241) compared with docetaxel (n=222; median overall survival was 15.7 month

234 e randomly allocated either ramucirumab plus docetaxel (n=263) or placebo plus docetaxel (n=267).

235 rumab plus docetaxel (n=263) or placebo plus docetaxel (n=267).

236 More evidence on the effects of docetaxel on survival is needed in the M0 disease settin

237 racted hazard ratios (HRs) of the effects of docetaxel or bisphosphonates on survival (time from rand

238 large randomised controlled trials combining docetaxel or bisphosphonates with standard of care in ho

239 thods Patients were randomly assigned 2:1 to docetaxel or cabazitaxel.

240 ring either standard of care with or without docetaxel or standard of care with or without bisphospho

241 /m(2) oral twice daily days 1-14, 75 mg/m(2) docetaxel) or with addition of gemcitabine (1000 mg/m(2)

242 ons testing the addition of zoledronic acid, docetaxel, or their combination to standard of care vers

243 etaxel plus placebo (n = 54) and gemcitabine-docetaxel plus bevacizumab (n = 53).

244 xel plus placebo) to 6.7 months (gemcitabine-docetaxel plus bevacizumab).

245 ), while the other half received 3 cycles of docetaxel plus capecitabine followed by 3 cycles of cycl

246 ed the efficacy and safety of treatment with docetaxel plus either ramucirumab-a human IgG1 VEGFR-2 a

247 all, 107 patients were accrued: gemcitabine-docetaxel plus placebo (n = 54) and gemcitabine-docetaxe

248 ase in median PFS from 4 months (gemcitabine-docetaxel plus placebo) to 6.7 months (gemcitabine-docet

249 model to evaluate the cost effectiveness of docetaxel plus trastuzumab (TH) with or without pertuzum

250 on adverse events of grade 3 or worse in the docetaxel, prednisone and custirsen group (n=501) compar

251 he MAINSAIL trial, 598 patients treated with docetaxel, prednisone or prednisolone, and placebo in th

252 taxel, prednisone, and lenalidomide (DPL) or docetaxel, prednisone, and a placebo (DP).

253 d for 214 (43%) of 501 patients treated with docetaxel, prednisone, and custirsen and 181 (36%) of 49

254 lled to the trial, of whom 510 were assigned docetaxel, prednisone, and custirsen and 512 were alloca

255 andomly assigned 1:1 centrally to either the docetaxel, prednisone, and custirsen combination or doce

256 s were attributable to 23 (5%) deaths in the docetaxel, prednisone, and custirsen group and 24 (5%) d

257 Patients assigned docetaxel, prednisone, and custirsen received weekly dos

258 survival 23.4 months [95% CI 20.9-24.8] with docetaxel, prednisone, and custirsen vs 22.0 months [19.

259 study of 1059 patients with mCRPC receiving docetaxel, prednisone, and lenalidomide (DPL) or docetax

260 the ASCENT2 trial, 526 patients treated with docetaxel, prednisone, and placebo in the MAINSAIL trial

261 (patients in group C received four cycles of docetaxel prior to FEC), and trastuzumab 6 mg/kg every 3

262 s in the risk of death with nivolumab versus docetaxel remained similar to those reported in the prim

263 Gemcitabine-docetaxel remains a standard first-line treatment for uL

264 also confirmed that NEPCa could increase the docetaxel resistance of neighboring PCa, and targeting t

265 ere, we found NEPCa cells could increase the docetaxel resistance of their neighboring PCa cells.

266 of increased AR function might then increase docetaxel resistance via increasing p21 expression.

267 hPTHrP may result in improving/restoring the docetaxel sensitivity to better suppress PCa.

268 ven neoadjuvant pertuzumab, trastuzumab, and docetaxel showed a significantly improved pathological c

269 ronic acid (SOC + ZA), standard of care plus docetaxel (SOC + Doc), or standard of care with both zol

270 andard of care with both zoledronic acid and docetaxel (SOC + ZA + Doc).

271 grammed death ligand 1 (PD-L1) inhibitors to docetaxel, the current standard of care in this setting.

272 Finally, after discontinuation of docetaxel therapy, median tumour growth (g) increased by

273 CA2 mutation does not preclude a response to docetaxel, there is overall a significant correlation be

274 men randomised) showed that the addition of docetaxel to standard of care improved survival.

275 The addition of docetaxel to standard of care should be considered stand

276 therapy, whereas it was only 0.3 QALMs when docetaxel + trastuzumab was used as a systemic therapy.

277 therapy, whereas it was only 0.3 QALMs when docetaxel + trastuzumab was used as a systemic therapy.

278 ced HER2-positive breast cancer treated with docetaxel, trastuzumab, and pertuzumab or placebo, highe

279 ced HER2-positive breast cancer treated with docetaxel, trastuzumab, and pertuzumab or placebo, highe

280 ng, disease progression following first-line docetaxel treatment established by radiographic evidence

281 Docetaxel treatment should become part of standard of ca

282 nt prostate cancer that had progressed after docetaxel treatment with a Karnofsky performance status

283 ll, of 757 participants, 349 (46%) completed docetaxel treatment.

284 cabazitaxel versus mitoxantrone after prior docetaxel treatment.

285 e-fluorouracil, leucovorin, oxaliplatin, and docetaxel) trial is a prospective, phase 2 trial of 252

286 This study compared gemcitabine and docetaxel versus doxorubicin as first-line treatment for

287 antly in patients allocated ramucirumab plus docetaxel versus placebo plus docetaxel (median 4.07 mon

288 (169 adverse events [67%] for selumetinib + docetaxel vs 115 adverse events [45%] for placebo + doce

289 n in the risk of death with nivolumab versus docetaxel was 28% (hazard ratio, 0.72; 95% CI, 0.62 to 0

290 Treatment with 8 or more cycles of docetaxel was associated with superior OS (hazard ratio

291 CA1/2 protein expression and the response to docetaxel was found.

292 Until 2010, docetaxel was the only agent with proven survival benefi

293 or targeted delivery of the chemotherapeutic docetaxel, we showed that bone tumor burden could be red

294 overall survival rates with nivolumab versus docetaxel were 23% (95% CI, 16% to 30%) versus 8% (95% C

295 In addition to docetaxel, which has been used for more than a decade, i

296 ycles of docetaxel alone; docetaxel with ZA; docetaxel with a single Sr89 dose after 6 cycles; or doc

297 ring androgen-deprivation therapy (ADT) plus docetaxel with ADT alone for initial metastatic hormone-

298 l with a single Sr89 dose after 6 cycles; or docetaxel with both ZA and Sr89.

299 kinase kinase (MEK) inhibitor selumetinib + docetaxel with docetaxel alone as a second-line therapy

300 us therapy, to receive treatment with either docetaxel with PANVAC (arm A) or docetaxel alone (arm B)

301 Up to 10 cycles of docetaxel alone; docetaxel with ZA; docetaxel with a single Sr89 dose aft

302 pembrolizumab 10 mg/kg, and 4.0 months with docetaxel, with no significant difference for pembrolizu

303 whether concomitant treatment with ADT plus docetaxel would result in longer overall survival than t